Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Honda, Masao ^a   Yamashita, Taro ^a   Yamashita, Tatsuya ^a   Arai, Kuniaki ^a   Sakai, Yoshio ^a   Sakai, Akito ^a   Nakamura, Mikiko ^a   Mizukoshi, Eishiro ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Acyclic retinoid; Gene expression; Hepatocellular carcinoma

Indexed keywords

INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; PERETINOIN; RNA; TUMOR SUPPRESSOR PROTEIN; WNT PROTEIN;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CEBPA GENE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CYP26B1 GENE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; ENTERITIS; FEMALE; G0S2 GENE; GENE EXPRESSION; GPRC5A GENE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IGFBP6 GENE; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PDGFC GENE; PERIPHERAL EDEMA; PRB4 GENE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RBP1 GENE; RHINOPHARYNGITIS; RNA ISOLATION; SIDE EFFECT; TGM2 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETINOIDS;

EID: 84876109081     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-191     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338. 10.1055/s-2007-1007122, 10518312.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699. 10.1056/NEJM199603143341104, 8594428.
6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200. 10.1055/s-2005-871198, 15918147.
7. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, Boix L, Visa J, Rodes J. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993, 18(5):1121-1126.
8. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138(4):299-306. 10.7326/0003-4819-138-4-200302180-00008, 12585827.
9. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009, 96(9):975-981. 10.1002/bjs.6731, 19672926.
10. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009, 1:CD001199.
11. Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, Roumilhac D, Canva V, Paris JC, Chaput JC. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003, 17(10):1247-1261. 10.1046/j.1365-2036.2003.01580.x, 12755838.
12. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24):1561-1567. 10.1056/NEJM199606133342402, 8628336.
13. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999, 340(13):1046-1047. 10.1056/NEJM199904013401315, 10189289.
14. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohno H, Matsushima-Nishiwaki R, Takano Y. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 2005, 51(2):197-206. 10.1207/s15327914nc5102_10, 15860442.
15. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohno H, Tanaka T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamin-einduced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 2004, 25(6):979-985. 10.1093/carcin/bgh093, 14742314.
16. Okusaka T, Ueno H, Ikeda M, Morizane C. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 2011, 41(6):542-552. 10.1111/j.1872-034X.2011.00800.x, 21501352.
17. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, Izumi N, Okusaka T, Ohashi Y, Makuuchi M. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 2010, 15s(28Suppl):4024.
18. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006, 44(5):1122-1138. 10.1002/hep.21383, 17058214.
19. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139(2):499-509. 10.1053/j.gastro.2010.04.049, 20434452.
20. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995, 207(1):382-388. 10.1006/bbrc.1995.1199, 7857292.
21. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002, 36(5):660-671. 10.1016/S0168-8278(02)00044-2, 11983450.
22. Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagama H, Imawari M, Moriwaki H, Muto Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994, 10(3):151-158. 10.1002/mc.2940100306, 7519016.
23. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002, 62(14):3997-4006.
24. Suzui M, Shimizu M, Masuda M, Lim JT, Yoshimi N, Weinstein IB. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 2004, 3(3):309-316.
25. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984, 73(6):1389-1393.
26. Sakabe T, Tsuchiya H, Endo M, Tomita A, Ishii K, Gonda K, Murai R, Takubo K, Hoshikawa Y, Kurimasa A. An antioxidant effect by acyclic retinoid suppresses liver tumor in mice. Biochem Pharmacol 2007, 73(9):1405-1411. 10.1016/j.bcp.2006.12.030, 17261273.
27. Okada H, Honda M, Campbell JS, Sakai Y, Yamashita T, Takebuchi Y, Hada K, Shirasaki T, Takabatake R, Nakamura M. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012, 72(17):4459-4471. 10.1158/0008-5472.CAN-12-0028, 22651928.
28. Tomaru Y, Nakanishi M, Miura H, Kimura Y, Ohkawa H, Ohta Y, Hayashizaki Y, Suzuki M. Identification of an inter-transcription factor regulatory network in human hepatoma cells by Matrix RNAi. Nucleic Acids Res 2009, 37(4):1049-1060. 2651797, 19129217.
29. Nakanishi M, Tomaru Y, Miura H, Hayashizaki Y, Suzuki M. Identification of transcriptional regulatory cascades in retinoic acid-induced growth arrest of HepG2 cells. Nucleic Acids Res 2008, 36(10):3443-3454. 10.1093/nar/gkn066, 2425469, 18445634.
30. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 2009, 284(1):345-353. 2610495, 18957410.
31. Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E. Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene 2003, 22(31):4924-4932. 10.1038/sj.onc.1206728, 12894236.
32. Ye X, Tao Q, Wang Y, Cheng Y, Lotan R. Mechanisms underlying the induction of the putative human tumor suppressor GPRC5A by retinoic acid. Cancer Biol Ther 2009, 8(10):951-962. 10.4161/cbt.8.10.8244, 19279407.
33. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-1327. 10.1002/hep.22506, 2597642, 18821591.
34. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010, 52(6):921-929. 10.1016/j.jhep.2009.12.034, 2905725, 20385424.
35. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007, 67(6):2736-2746. 10.1158/0008-5472.CAN-06-4433, 2276570, 17363595.
36. Fields AL, Soprano DR, Soprano KJ. Retinoids in biological control and cancer. J Cell Biochem 2007, 102(4):886-898. 10.1002/jcb.21530, 17902161.
37. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004. 10.1056/NEJMoa0804525, 2963075, 18923165.
38. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010, 45(2):146-152. 10.1007/s00535-009-0164-1, 19997856.